健脾消癌方治疗对大肠癌肝转移患者临床疗效、血管生成因子及QLQ-c30评分的影响  

Effect of Jianpi Xiaoai Recipe on Clinical Efficacy,Angiogenesis Factors and QLQ-c30 Score for Patients with Liver Metastases of Colorectal Cancer

作　　者：彭巍[1] 唐建清[1] 龚辉 简小兰[2] PENG Wei;TANG Jianqing;GONG Hui;无(Department of Oncology,the Affiliated Hospital of Hu’nan Academy of Traditional Chinese Medicine,Changsha Hunan 410006,China;Department of Radiotherapy,the Affiliated Hospital of Hu’nan Academy of Traditional Chinese Medicine,Changsha Hu'nan 410006,China)

机构地区：[1]湖南省中医药研究院附属医院肿瘤科,湖南长沙410006 [2]湖南省中医药研究院附属医院放疗科,湖南长沙410006

出　　处：《四川中医》2021年第8期76-79,共4页Journal of Sichuan of Traditional Chinese Medicine

基　　金：湖南省自然基金项目(编号:2019JJ50349);湖南省自然基金项目(编号:2019JJ50344);国家自然科学基金资助项目(编号:81904109、81774287)。

摘　　要：目的:观察健脾消癌方治疗对大肠癌肝转移患者临床疗效、血管生成因子及QLQ-c30评分的影响。方法:2015年6月~2020年6月本院进行根治手术治疗的78例大肠癌肝转移患者,根据治疗方案不同分为对照组40例(FOLFOX4方案全身静脉化疗或口服卡培他滨化疗)和观察组38例(在对照组的基础上予以健脾消癌方治疗)。对比2组患者治疗后临床疗效、治疗前后血清血管内皮生长因子(Vascular Endothelial Growth Factor,VEGF)、血管内皮生长因子受体-2(Vascular Endothelial Growth Factor Receptor 2,VEGFR-2)的浓度变化情况;采用生活质量评分量表(Questionnaire-Core30,QLQ-C30)评估2组患者治疗前后生活质量,观察并记录不良反应事件发生率。结果:(1)观察组疾病控制率(71.05%)显著高于对照组(47.50%)(P<0.05)。(2)治疗后2个月,2组VEGF、VEGFR-2水平均明显降低,观察组VEGF、VEGFR-2水平显著低于对照组(P<0.05)。(3)治疗后2个月,2组患者社会功能、物质生活、躯体功能、心理功能评分均明显升高,其中观察组显著高于对照组(P<0.05)。(4)2组患者治疗后不良反应总发生率比较差异无统计学意义(P>0.05)。结论:健脾消癌方是一种临床疗效好、安全性高的的治疗方药,应用于大肠癌肝转移患者中可有效抑制患者肿瘤血管生成,提升患者生活质量水平。Objective:To explore the effect of Jianpi Xiaoai Recipe on clinical efficacy,angiogenesis factors and QLQ-c30 score for patients with liver metastases of colorectal cancer.Methods:78 patients with liver metastases of colorectal cancer treated with radical surgical treatment in our hospital from June 2015 to June 2020 were selected.According to the different treatment plans,they were divided into a controlled group,40 cases(FOLFOX4 regimen,systemic intravenous chemotherapy or oral capecitabine chemotherapy)and an observation group,38 cases(on the basis of treatment of the controlled group,treated with Jianpi Xiaoai Recipe).The clinical efficacy of patients after treatment,the changes in serum vascular endothelial growth factor(VEGF)and vascular endothelial growth factor receptor-2(VEGFR-2)levels before and after treatment were compared between the two groups.The Questionnaire-Core30(QLQ-C30)was used to assess the quality of life of the two groups before and after treatment,and the incidence of adverse events was observed and recorded.Results:(1)The disease control rate of the observation group(71.05%)was significantly higher than that of the controlled group(47.50%)(P<0.05).(2)Two months after treatment,the levels of VEGF and VEGFR-2 in the two groups significantly reduced,and the levels of VEGF and VEGFR-2 in the observation group were significantly lower than those in the controlled group(P<0.05).(3)Two months after treatment,the social function,material life,physical function,and psychological function scores of the patients in the two groups significantly increased,and the scores of the observation group were significantly higher than those of the controlled group(P<0.05).(4)There was no significant difference in the total incidence of adverse reactions between the two groups after treatment(P>0.05).Conclusion:Jianpi Xiaoai Recipe is a therapeutic prescription with good clinical efficacy and high safety.It can effectively inhibit tumor angiogenesis in patients with liver metastasis of colorectal cancer and imp

关 键 词：健脾消癌方 大肠癌 肝转移 血管生成因子QLQ-c30评分 

分 类 号：R735.34[医药卫生—肿瘤]